Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · IEX Real-Time Price · USD
0.470
-0.019 (-3.87%)
At close: Jul 19, 2024, 4:00 PM
0.500
+0.030 (6.38%)
Pre-market: Jul 22, 2024, 7:27 AM EDT
Company Description
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.
Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Enveric Biosciences, Inc.
| Country | United States |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Joseph Edward Tucker Ph.D. |
Contact Details
Address: 4851 Tamiami Trail N, Suite 200 Naples, Florida 34103 United States | |
| Phone | 239-302-1707 |
| Website | enveric.com |
Stock Details
| Ticker Symbol | ENVB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000890821 |
| CUSIP Number | 29405E208 |
| ISIN Number | US29405E2081 |
| Employer ID | 95-4484725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | Chief Executive Officer and Director |
| Kevin M. Coveney CPA | Chief Financial Officer |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2024 | 8-K | Current Report |
| Jul 8, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 29, 2024 | 8-K | Current Report |
| May 23, 2024 | 8-K | Current Report |
| May 17, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | 8-K | Current Report |
| May 3, 2024 | 424B5 | Filing |
| May 3, 2024 | 8-K | Current Report |
| Apr 16, 2024 | ARS | Filing |